The Solutions for Drug-Resistant Infections 2017 conference will bring together leading scientific, medical and industry experts to discuss new solutions and an integrated ‘one health’ approach to the global challenge of drug-resistant pathogens.

Conference theme

New drugs for drug-resistant infections

Who should attend?

This conference will provide a forum for senior research leaders and key industry representatives working in the fields of microbiology, virology, parasitology, genomics, pharmacology and medicinal chemistry to network and discuss new ways to solve the global challenge of drug-resistant infections in human and animal health.

Our goal for SDRI 2017 is to lead a concerted discussion to set three priorities and guide research efforts towards global solutions for drug resistance research. 

Conference session highlights

  • Antimicrobial drug discovery
  • Improvements to existing anti-infective agents and repurposing
  • New drug targets
  • Alternate therapies
  • Navigating the pipeline
  • International models and funding
  • Vector control and vaccines

Speaker highlights

Confirmed plenary speakers

  • Professor Dame Sally Davies DBE FMedSci FRS, Chief Medical Officer for England
  • Professor Ramanan Laxminarayan, Public Health Foundation of India
  • Professor John Rex, Chief Strategy Officer, CARB-X; and Voting Member, US PACCARB

Confirmed keynote speakers

  • Dr Jean-Pierre Paccaud, DNDi
  • A/Professor Heidi Drummer, Burnet Institute
  • Professor Ian Gilbert, Drug Discovery Unit, University of Dundee
  • Professor Bob Hancock, University of British Columbia
  • Dr Timothy Jinks, Strategy Development Lead, Wellcome Trust
  • Dr Line Matthiessen-Guyader, Head of Unit, Research Directorate-General, Biotechnology, Agriculture and Food Research, European Commission
  • Dr Terry Roemer, Head of Antimicrobial Discovery, Merck, USA
  • Dr David Shlaes, Anti-infective Consultant, USA
  • A/Professor Gilda Tachedjian, Burnet Institute 
  • Professor Man-Wah Tam, Director, Infectious Disease, Genentech
  • Professor Elizabeth Winzeler, University of California
  • Professor Gerry Wright, Michael G. DeGroote Institute for Infectious Disease Research, UK
  • Dr Zuoyu Xu, National Institute of Allergy and Infectious Diseases

Why SDRI 2017?

By 2050, it is estimated that nearly 10 million annual deaths globally will be attributable to bacterial antimicrobial resistance alone (Source: Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, 2014). 

Globally, incidences of drug resistance in bacterial infections, dengue, tuberculosis and malaria continue to rise. Diseases caused by these pathogens are becoming more deadly and difficult to treat. New therapies are urgently needed to prevent a return to the preantibiotic era, when even simple infections caused death.

Visit the conference website



Brisbane Convention and Exhibition Centre, Merivale St & Glenelg Street, South Brisbane QLD 4101